A Multicenter, dOuble-blind, ranDomized, Placebo-controlled, Parallel-group Study to Determine the effIcacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With FabrY Disease

Trial Profile

A Multicenter, dOuble-blind, ranDomized, Placebo-controlled, Parallel-group Study to Determine the effIcacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With FabrY Disease

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2018

At a glance

  • Drugs Lucerastat (Primary)
  • Indications Fabry's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms MODIFY
  • Sponsors Idorsia Pharmaceuticals
  • Most Recent Events

    • 08 Feb 2018 New trial record
    • 07 Feb 2018 Status changed from planning to not yet recruiting.
    • 06 Feb 2018 According to an Idorsia Pharmaceuticals media release, this trial is expected to begin in first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top